VNDA · Insider Trading
Vanda Pharmaceuticals Inc.
Every open-market purchase and sale reported by VNDA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-08 | Anne Sempowski Ward | Director | A | +41,600 | — |
| 2026-06-08 | Richard W Dugan | Director | A | +41,600 | — |
| 2026-06-08 | Tage Honore | Director | A | +41,600 | — |
| 2026-06-08 | Phaedra Chrousos | Director | A | +41,600 | — |
| 2026-06-08 | Stephen Ray Mitchell | Director | A | +41,600 | — |
| 2026-06-08 | Charles Cliff Duncan | Director | A | +41,600 | — |
| 2026-06-08 | Daniel Patrick McGuire | SVP, GC and Secretary | A | +80,000 | — |
| 2026-05-20 | Stephen Ray Mitchell | Director | G | −25,836 | — |
| 2026-04-24 | Charles Cliff Duncan | Director | A | +57,101 | — |
| 2026-03-04 | Mihael Hristos Polymeropoulos | President and CEO | Sell | −156,235 | −$1.28M |
| 2026-03-04 | Timothy Williams | SVP & General Counsel | Sell | −42,434 | −$350.76K |
| 2026-03-04 | Gunther Birznieks | SVP, Business Development | Sell | −42,431 | −$350.73K |
| 2026-03-04 | Joakim Wijkstrom | SVP, Chief Marketing Officer | Sell | −30,800 | −$254.59K |
| 2026-03-04 | Kevin Patrick Moran | SVP, CFO & Treasurer | Sell | −42,442 | −$350.82K |
| 2026-02-24 | Tage Honore | Director | Sell | −30,000 | −$240.90K |
| 2026-02-19 | Timothy Williams | SVP & General Counsel | A | +125,000 | — |
| 2026-02-19 | Mihael Hristos Polymeropoulos | President and CEO | A | +525,000 | — |
| 2026-02-19 | Joakim Wijkstrom | SVP, Chief Marketing Officer | A | +125,000 | — |
| 2026-02-19 | Gunther Birznieks | SVP, Business Development | A | +125,000 | — |
| 2026-02-19 | Kevin Patrick Moran | SVP, CFO & Treasurer | A | +125,000 | — |
| 2025-08-08 | Mihael Hristos Polymeropoulos | President and CEO | Buy | +10,000 | +$41.50K |
| 2025-06-16 | Stephen Ray Mitchell | Director | Sell | −7,000 | −$32.13K |
| 2025-06-09 | Phaedra Chrousos | Director | A | +59,225 | — |
| 2025-06-09 | Tage Honore | Director | A | +59,225 | — |
| 2025-06-09 | Richard W Dugan | Director | A | +59,225 | — |
| 2025-06-09 | Stephen Ray Mitchell | Director | A | +59,225 | — |
| 2025-06-09 | Anne Sempowski Ward | Director | A | +59,225 | — |
| 2025-05-21 | Mihael Hristos Polymeropoulos | President and CEO | Buy | +10,000 | +$44.00K |
| 2025-05-19 | Mihael Hristos Polymeropoulos | President and CEO | Buy | +20,000 | +$84.47K |
| 2025-03-06 | Mihael Hristos Polymeropoulos | President and CEO | Buy | +10,000 | +$50.15K |
| 2025-03-05 | Mihael Hristos Polymeropoulos | President and CEO | Buy | +10,000 | +$50.20K |
| 2025-03-04 | Kevin Patrick Moran | SVP, CFO & Treasurer | F | −26,941 | −$128.24K |
| 2025-03-04 | Timothy Williams | SVP & General Counsel | F | −26,941 | −$128.24K |
| 2025-03-04 | Mihael Hristos Polymeropoulos | President and CEO | MIXED | −85,999 | −$409.91K |
| 2025-03-04 | Gunther Birznieks | SVP, Business Development | F | −26,941 | −$128.24K |
| 2025-03-04 | Joakim Wijkstrom | SVP, Chief Marketing Officer | F | −15,520 | −$73.88K |
| 2025-02-28 | Mihael Hristos Polymeropoulos | President and CEO | Buy | +10,000 | +$47.60K |
| 2025-02-27 | Mihael Hristos Polymeropoulos | President and CEO | Buy | +10,000 | +$47.60K |
| 2025-02-26 | Mihael Hristos Polymeropoulos | President and CEO | Buy | +10,000 | +$47.65K |
| 2025-02-25 | Mihael Hristos Polymeropoulos | President and CEO | Buy | +10,000 | +$44.64K |
| 2025-02-24 | Kevin Patrick Moran | SVP, CFO & Treasurer | Buy | +2,000 | +$8.78K |
| 2025-02-20 | Timothy Williams | SVP & General Counsel | A | +125,000 | — |
| 2025-02-20 | Joakim Wijkstrom | SVP, Chief Marketing Officer | A | +125,000 | — |
| 2025-02-20 | Kevin Patrick Moran | SVP, CFO & Treasurer | A | +125,000 | — |
| 2025-02-20 | Gunther Birznieks | SVP, Business Development | A | +125,000 | — |
| 2025-02-20 | Mihael Hristos Polymeropoulos | President and CEO | A | +450,000 | — |
| 2024-11-18 | Stephen Ray Mitchell | Director | Sell | −5,000 | −$25.86K |
| 2024-07-29 | Kevin Patrick Moran | SVP, CFO & Treasurer | Sell | −2,251 | −$13.33K |
| 2024-05-24 | Phaedra Chrousos | Director | A | +21,887 | — |
| 2024-05-21 | Anne Sempowski Ward | Director | A | +20,529 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Mihael Hristos Polymeropoulos | President and CEO | 2,704,496 | $10.66M |
| Gunther Birznieks | SVP, Business Development | 494,197 | $1.95M |
| Kevin Patrick Moran | SVP, CFO & Treasurer | 412,015 | $1.62M |
| Timothy Williams | SVP & General Counsel | 377,450 | $1.49M |
| Joakim Wijkstrom | SVP, Chief Marketing Officer | 333,469 | $1.31M |
| Richard W Dugan | Director | 219,054 | $863.07K |
| Phaedra Chrousos | Director | 164,950 | $649.90K |
| Anne Sempowski Ward | Director | 160,667 | $633.03K |
| Tage Honore | Director | 135,069 | $532.17K |
| Stephen Ray Mitchell | Director | 112,846 | $444.61K |
| Daniel Patrick McGuire | SVP, GC and Secretary | 109,982 | $433.33K |
| Charles Cliff Duncan | Director | 98,701 | $388.88K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the VNDA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.